A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy

被引：88

作者：

Alkhalaf, Alaa ^{[1
,4
]}

Klooster, Astrid ^{[1
]}

van Oeveren, Willem ^{[2
]}

Achenbach, Ulrike ^{[3
]}

Kleefstra, Nanne ^{[4
,5
]}

Slingerland, Robbert J. ^{[6
]}

Mijnhout, G. Sophie ^{[7
]}

Bilo, Henk J. G. ^{[1
,4
,7
]}

Gans, Reinold O. B. ^{[1
]}

Navis, Gerjan J. ^{[1
]}

Bakker, Stephan J. L. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, NL-9713 AV Groningen, Netherlands

[2] Univ Med Ctr Groningen, Dept Biomed Engn, NL-9713 AV Groningen, Netherlands

[3] Worwag Pharma GmbH & Co KG, Boblingen, Germany

[4] Isala Clin, Ctr Diabet, Zwolle, Netherlands

[5] Langerhans Med Res Grp, Zwolle, Netherlands

[6] Isala Clin, Dept Clin Chem, Zwolle, Netherlands

[7] Isala Clin, Dept Internal Med, Zwolle, Netherlands

来源：

DIABETES CARE | 2010年 / 33卷 / 07期

关键词：

HIGH-DOSE THIAMINE; DISEASE; DAMAGE;

D O I：

10.2337/dc09-2241

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

OBJECTIVE - To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy. RESEARCH DESIGN AND METHODS - Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43). RESULTS - Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P < 0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion. CONCLUSIONS - In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.

引用

页码：1598 / 1601

页数：4

共 15 条

[1]

Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine [J].

Babaei-Jadidi, R ;

Karachalias, N ;

Ahmed, N ;

Battah, S ;

Thornalley, PJ .

DIABETES, 2003, 52 (08) :2110-2120

[2]

Bakker SJL, 1997, DIABETOLOGIA, V40, P741

[3]

Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? [J].

Bilous, R. .

DIABETIC MEDICINE, 2008, 25 :25-29

[4]

Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703

[5]

Renal protection in diabetes: Role of glycemic control [J].

Fioretto, Paola ;

Bruseghin, Marino ;

Berto, Ilaria ;

Gallina, Pietro ;

Manzato, Enzo ;

Mussap, Michele .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (04) :S86-S89

[6]

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy [J].

Hammes, HP ;

Du, XL ;

Edelstein, D ;

Taguchi, T ;

Matsumura, T ;

Ju, QD ;

Lin, JH ;

Bierhaus, A ;

Nawroth, P ;

Hannak, D ;

Neumaier, M ;

Bergfeld, R ;

Giardino, I ;

Brownlee, M .

NATURE MEDICINE, 2003, 9 (03) :294-299

[7]

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

[8]

THE MEASUREMENT OF ERYTHROCYTE TRANSKETOLASE ACTIVITY ON A DISCRETE ANALYZER [J].

MILNER, CR ;

BUTTERY, JE ;

CHAMBERLAIN, BR .

JOURNAL OF AUTOMATIC CHEMISTRY, 1982, 4 (04) :183-185

[9]

NATH KA, 1992, AM J KIDNEY DIS, V20, P1

[10]

High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study [J].

Rabbani, N. ;

Alam, S. S. ;

Riaz, S. ;

Larkin, J. R. ;

Akhtar, M. W. ;

Shafi, T. ;

Thornalley, P. J. .

DIABETOLOGIA, 2009, 52 (02) :208-212

← 1 2 →